Inventiva S.A. (IVA) stock
Close on Nov 12, 2026Market cap $749.76MP/E –Yield –
Inventiva S.A. saw revenue fall 51.3% to €4.48M over fiscal 2025. At the latest close the market valued the company at €672.19M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- €672.19M
- P/E ratio
- –
- Price to sales
- 149.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €4.48M
- EPS, diluted
- -1.90 EUR
Trading
- Previous close
- $4.01
- Open
- $3.98
- Day's range
- $3.87 – $4.11
- Volume
- 2,503,731
- Average volume (20 days)
- 2,769,864
- Beta (5 years)
- 0.85
- RSI (14 days)
- 60.1
- Volatility (1 year)
- 65.1%
- Relative volume
- 1.31×
- WACC
- 9.1%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IVA | S&P 500 | Difference | IVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +24.4% | -2.7% | +27.1 pts | ||
| 3 months | -17.1% | -1.7% | −15.3 pts | ||
| Year to date | -16.6% | +11.9% | −28.5 pts | ||
| 1 year | -4.2% | +12.0% | −16.2 pts | ||
| 3 years | +5.1% | +78.2% | −73.0 pts | +1.7% | +21.2% |
| 5 years | -72.0% | +73.2% | −145.2 pts | -22.5% | +11.6% |
| 10 years | +3780.0% | +309.6% | +3470.4 pts | +44.2% | +15.1% |
Nine years at a glance
Fiscal years 2017 to 2025, EUR
Revenue
Operating income
EPS, diluted
Press releases
Releases Inventiva filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Inventiva
Pharmaceutical Preparations
Inventiva S.A. is a clinical-stage biopharmaceutical company that develops oral small molecule therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Its sole drug candidate in active development is lanifibranor, a pan-PPAR activator designed to induce anti-fibrotic, anti-inflammatory, and metabolic improvements in patients suffering from progressive liver diseases. The company previously pursued earlier-stage oncology and genetic disorder programs, but it has discontinued non-lanifibranor research to dedicate all resources to its lead compound. Its prospective end users are adult patients diagnosed with MASH, non-alcoholic fatty liver disease, and related liver conditions such as compensated cirrhosis.
Company profile, executives and historyInventiva stock: common questions
What is Inventiva's stock price?
IVA closed at $3.88 on Nov 12, 2026, down 3.24% on the day.
What is Inventiva's market cap?
Inventiva was worth $749.76M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IVA's P/E ratio?
Inventiva lost money over fiscal 2025 (diluted EPS -1.90 EUR), so it has no meaningful P/E ratio.
How much revenue does Inventiva make?
Inventiva reported revenue of €4.48M for fiscal 2025, down 51.3% from a year earlier.
Does Inventiva pay a dividend?
No. Inventiva has not paid a cash dividend over the last twelve months.
How has IVA stock performed over the past year?
Including dividends, IVA returned -4.2% over the past year, against +12.0% for the S&P 500.
Who are Inventiva's competitors?
Companies most similar to Inventiva by business, industry and size include TVRD, MTRI, TRDA, ANL, TRAW.
See a number that looks wrong?